GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Level Bio AB (XSAT:LEVBIO) » Definitions » Debt-to-Equity

Level Bio AB (XSAT:LEVBIO) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Level Bio AB Debt-to-Equity?

Level Bio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr7.96 Mil. Level Bio AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Level Bio AB's Debt-to-Equity or its related term are showing as below:

XSAT:LEVBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.49   Max: 1.57
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of Level Bio AB was 1.57. The lowest was 0.03. And the median was 0.49.

XSAT:LEVBIO's Debt-to-Equity is ranked better than
64.77% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs XSAT:LEVBIO: 0.14

Level Bio AB Debt-to-Equity Historical Data

The historical data trend for Level Bio AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Level Bio AB Debt-to-Equity Chart

Level Bio AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 0.40 0.04 0.03 0.11

Level Bio AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.11 -

Competitive Comparison of Level Bio AB's Debt-to-Equity

For the Diagnostics & Research subindustry, Level Bio AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Level Bio AB's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Level Bio AB's Debt-to-Equity falls into.



Level Bio AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Level Bio AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Level Bio AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Level Bio AB  (XSAT:LEVBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Level Bio AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Level Bio AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Level Bio AB (XSAT:LEVBIO) Business Description

Traded in Other Exchanges
Address
Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
AlphaHelix Molecular Diagnostics AB develops, manufactures, and markets products for DNA-identification and quantitation in molecular diagnostics and life science research. Its product inlcude Rob, BugScreener MRSA, and aAmp. The company applications inlcude Diagnostics, PCR and Liquid handling.

Level Bio AB (XSAT:LEVBIO) Headlines

No Headlines